Anti-Infectives
Targo
Levofloxacin 750 mg - 10 Film-coated tablets
Therapeutic Indications:
Targo tablets are indicated for the treatment of adults ( >18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section When the administration offers a route of administration advantageous to the
Patient (e.g., the patient cannot tolerate an oral dosage form).
Fluoroquinolones should be reserved for use in patients who have no other treatment options for acute bacterial sinusitis, (ABS), acute bacterial exacerbation of chronic bronchitis (ABECB), and uncomplicated urinary tract infections
(UTI).
Fluoroquinolones should not be used in the following indications:
To treat infections that might get better without treatment or are not severe (such as throat infections) .
To treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis.
For preventing traveler’s diarrhea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder).
To treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used.
Nosocomial Pneumonia:
targo tablets are indicated for the treatment of nosocomial pneumonia due to methicillin -susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia colt, Klebsiella pneumonia, Haemophilus influenza, or Streptococcus pneumonia.
Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeroginosais a documented or presumptive pathogen, combination therapy with an anti-pseudomonal B-lactam is recommended
Community-Acquired Pneumonia:
7 to 14-day Treatment Regimen.
Targo tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumonia, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, mycoplasma pneumonia.
MDRSP isolates are isolates resistant to two or more of the following antibacterial penicillin (MIC 22 mcg/mL), 2nd generation cephalosporins, cefuroxime, macrolides, tetracyclines, and trimethoprim/sulfamethoxazole .
Community-Acquired Pneumonia:
5-day Treatment Regimen.
Targo tablets are indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumonia
(excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenza, Haemophilus parainjuenzae, Mycoplasma pneumonia, or Chlamydophila pneumonia .
Complicated Skin and Skin Structure Infections:
Targo tablets are indicated for the treatment of complicated skin and skin structure infections due to methicillin -susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis .
Uncomplicated Skin and Skin Structure Infections:
Targo tablets are indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, and wound infections, due to methicillin -susceptible Staphylococcus sorrier, or Streptococcus pyogenes.